title: Carnitine serum levels and levocarnitine administration in multiple sclerosis patients treated with natalizumab.
authors.forename: M
authors.initials: M
authors.lastname: Laffon-Pioger
authors.forename: F
authors.initials: F
authors.lastname: Rocher
authors.forename: C
authors.initials: C
authors.lastname: Caruba
authors.forename: M
authors.initials: M
authors.lastname: Cohen
authors.forename: P
authors.initials: P
authors.lastname: Thomas
authors.forename: C
authors.initials: C
authors.lastname: Lebrun
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects; D002331:Carnitine / Q000008:administration & dosage* / Q000097:blood* / Q000172:deficiency; D015331:Cohort Studies; D015673:Fatigue Syndrome, Chronic / Q000097:blood / Q000188:drug therapy / Q000209:etiology; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D009103:Multiple Sclerosis / Q000097:blood* / Q000150:complications / Q000188:drug therapy*; D000069442:Natalizumab; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D000069442:Natalizumab; D002331:Carnitine